{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreig4qhtoc62pfzitxdpv246xk7nf4ywb5ksejhj4sbf2yfgkqp4p5u",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mehsyk7b2f72"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigxgcb2jcirykbgv4ercpoyfepcpji6hjxekoijwzsdz6bp5km2rm"
    },
    "mimeType": "image/jpeg",
    "size": 494924
  },
  "path": "/news/2026-02-fda-primary-cns-lymphoma.html",
  "publishedAt": "2026-02-09T20:30:01.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Oncology & Cancer"
  ],
  "textContent": "Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system lymphoma, a rare and aggressive lymphoma of the brain and spinal cord. The change is expected to expand access to commercial CAR T-cell therapy for eligible patients with relapsed or refractory disease.",
  "title": "Research helps drive FDA label update for primary CNS lymphoma"
}